Year: 2016
Type: review
Abstract: Immune escape strategies aimed to avoid T-cell recognition, including the loss of tumor MHC class I expression, are commonly found in malignant cells. Tumor immune escape has proven to have a negative effect on the clinical outcome of cancer immunotherapy, including treatment with antibodies blocking immune checkpoint molecules. Hence, there is an urgent need to develop novel approaches to overcome tumor immune evasion. MHC class I antigen presentation is often affected in human cancers and the capacity to induce upregulation of MHC class I cell surface expression is a critical step in the induction of tumor rejection. This review focuses on characterization of rejection, escape, and dormant profiles of tumors and its microenvironment with a special emphasis on the tumor MHC class I expression. We also discuss possible approaches to recover MHC class I expression on tumor cells harboring reversible/'soft' or irreversible/'hard' genetic lesions. Such MHC class I recovery approaches might well synergize with complementary forms of immunotherapy.
Source: Current Opinion in Immunology
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $4,410
Awards: G1090949375, G1533251534, La latencia en el proceso metastásico como una nueva estrategia para destruir las células cancerosas, G2582249599, G2620658983, G2724427253, G2806354226, G2843475755, G3532582885, G3559709381, G3948329602, G4577874406, G4635409065, HLA de clase I en la progresión metastásica y la resistencia a la inmunoterapia de nueva generacion: Implicaciones en el escape inmunológico del cáncer, G5471213530, G5593807214, G6105522115, G6481729048, G6871965997, G6884116100, G6920163475, G6965972438, G7310115001, G8078908975
OpenAlex ID: W2285621780